Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 56 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
SOLME PHARMA from Brecht, company number BE0538952685, closed financial year 2025 with a result of € 79,875 after tax. For that financial year SOLME PHARMA recorded a gross margin of € 134,825 and equity of € 1 million. Compared with financial year 2024, the result moved from € 108,008 to € 79,875. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 25, 2026.
€ 1 million
▲ 9% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 79,875
▼ 26% vs 2024
Profit after tax over the fiscal year.
€ 114,750
▲ 25% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 983,249.
Debts at end 2025
€ 712,633
▼ 12% vs 2024
€ 80,000 is repaid this year. At this pace the long-term loan is gone in ≈ 9 years.
€ 778
▲ 131% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 29,334
▲ 5% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 156,223 | € 170,620 | € 174,813 | € 134,825 | ▼ 23% |
| Profit after taxes | € 97,598 | € 107,250 | € 108,008 | € 79,875 | ▼ 26% |
| Equity | € 770,834 | € 863,966 | € 921,974 | € 1,001,849 | ▲ 9% |
| Total debts | € 1,061,403 | € 974,322 | € 936,310 | € 841,175 | ▼ 10% |
| Cash | € 86,488 | € 111,068 | € 91,585 | € 114,750 | ▲ 25% |
| Retained profit | € 752,234 | € 845,366 | € 903,374 | € 983,249 | ▲ 9% |
| Dividend | € 0 | € 14,118 | € 50,000 | € 0 | ▼ 100% |
| Bank debt | € 1,011,934 | € 905,967 | € 812,633 | € 712,633 | ▼ 12% |
| Balance sheet total | € 1,832,236 | € 1,838,288 | € 1,858,285 | € 1,843,024 | ▼ 1% |
Key figures of SOLME PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to SOLME PHARMA?
What happened at SOLME PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 79,875 (▼ 26% vs 2024). filed late Source: NBB ↗
- New establishment in Brecht. KBO
- Melissa Sol became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 97,598 profit in 2022 to € 79,875 profit in 2025.
Paid € 120,581 in corporate taxes since 2022.
Best year ever: 2024, with € 108,008 profit.
Paid out € 64,118 in dividends to the owners in total.
Management
Behind SOLME PHARMA is Melissa Sol. It owns 93.3% of Apotheek St.-Job itself.
Directors
According to the 2025 annual accounts
since 2013
Establishments
Establishment units
Physical locations of this company
Eikenlei 13 box B
2960 Brecht
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0538.952.685
- VAT number
- BE 0538.952.685
- Registered office
- Eikenlei 13 bus B, 2960 Brecht
- Names & denominations
- SOLME PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 16 September 2013
- Peppol
- Active · Active since 14 May 2025
- Activities · NACE
Activiteiten van holdings
Holdings